prikaz prve stranice dokumenta Cladribine tablets in people with relapsing multiple sclerosis: A real-world multicentric study from southeast European MS centers
Access restricted to students and staff of home institution
Scientific paper - Original scientific paper
Cladribine tablets in people with relapsing multiple sclerosis: A real-world multicentric study from southeast European MS centers
Journal of Neuroimmunology, 382 (2023); 578164. https://doi.org/10.1016/j.jneuroim.2023.578164
Adamec, Ivan; Brecl Jakob, Gregor; Rajda, Cecilia; Drulović, Jelena; Radulović, Ljiljana; Bašić Kes, Vanja; Lazibat, Ines; Rimac, Julija; Cindrić, Igor; Gržinčić, Tihana; Abičić, Ana; Barun, Barbara; Gabelić, Tereza; Gomezelj, Sarah; Mesaroš, Šarlota; Pekmezović, Tatjana; Klivényi, Péter; Krbot Skorić, Magdalena; Habek, Mario More authors...

Cite this document

Adamec, I., Brecl Jakob, G., Rajda, C., Drulović, J., Radulović, Lj., Bašić Kes, V. ... Habek, M. (2023). Cladribine tablets in people with relapsing multiple sclerosis: A real-world multicentric study from southeast European MS centers. Journal of Neuroimmunology, 382.. doi: 10.1016/j.jneuroim.2023.578164

Adamec, Ivan, et al. "Cladribine tablets in people with relapsing multiple sclerosis: A real-world multicentric study from southeast European MS centers." Journal of Neuroimmunology, vol. 382, 2023. https://doi.org/10.1016/j.jneuroim.2023.578164

Adamec, Ivan, Gregor Brecl Jakob, Cecilia Rajda, Jelena Drulović, Ljiljana Radulović, Vanja Bašić Kes, Ines Lazibat, et al. "Cladribine tablets in people with relapsing multiple sclerosis: A real-world multicentric study from southeast European MS centers." Journal of Neuroimmunology 382 (2023). https://doi.org/10.1016/j.jneuroim.2023.578164

Adamec, I., et al. (2023) 'Cladribine tablets in people with relapsing multiple sclerosis: A real-world multicentric study from southeast European MS centers', Journal of Neuroimmunology, 382. doi: 10.1016/j.jneuroim.2023.578164

Adamec I, Brecl Jakob G, Rajda C, Drulović J, Radulović Lj, Bašić Kes V, and sur.. Cladribine tablets in people with relapsing multiple sclerosis: A real-world multicentric study from southeast European MS centers. Journal of Neuroimmunology [Internet]. 2023 September [cited 2024 December 07];382. doi: 10.1016/j.jneuroim.2023.578164

I. Adamec, et al., "Cladribine tablets in people with relapsing multiple sclerosis: A real-world multicentric study from southeast European MS centers", Journal of Neuroimmunology, vol. 382, September 2023. [Online]. Available at: https://urn.nsk.hr/urn:nbn:hr:220:430848. [Accessed: 07 December 2024]

Please login to the repository to save this object to your list.
Metadata
Title (english)Cladribine tablets in people with relapsing multiple sclerosis: A real-world multicentric study from southeast European MS centers
AuthorIvan Adamec
AuthorGregor Brecl Jakob
AuthorCecilia Rajda
AuthorJelena Drulović
AuthorLjiljana Radulović
MBZ: 74741
AuthorVanja Bašić Kes
AuthorInes Lazibat
AuthorJulija Rimac
AuthorIgor Cindrić
AuthorTihana Gržinčić
AuthorAna Abičić
AuthorBarbara Barun
AuthorTereza Gabelić
AuthorSarah Gomezelj
AuthorŠarlota Mesaroš
AuthorTatjana Pekmezović
AuthorPéter Klivényi
AuthorMagdalena Krbot Skorić
AuthorMario Habek
Author's institution(Sestre milosrdnice University Hospital Center)
Scientific / art field,
discipline and subdiscipline		BIOMEDICINE AND HEALTHCARE
Clinical Medical Sciences
Neurology
Abstract (english)
Background: Cladribine is an oral disease-modifying drug authorized by the European Medicine Agency for the treatment of highly active relapsing multiple sclerosis (MS). Objectives: To provide real-world evidence of cladribine’s effectiveness and safety in people with MS (pwMS). Methods: A retrospective observational multi-center, multi-national study of pwMS who were started on cladribine tablets in ten centers from five European countries. Results: We identified 320 pwMS treated with cladribine tablets. The most common comorbidities were arterial hypertension and depression. Three patients had resolved hepatitis B infection, while eight had positive Quantiferon test prior to cladribine commencement. There were six pwMS who had malignant diseases, but all were non-active. During year 1, 91.6% pwMS did not have EDSS worsening, 86.9% were relapse-free and 72.9% did not have MRI activity. During the second year, 90.2% did not experience EDSS worsening, 86.5% were relapse-free and 75.5% did not have MRI activity. NEDA-3 was present in 58.0% pwMS in year 1 and in 54.2% in year 2. In a multivariable logistic regression model age positively predicted NEDA-3 in year 1. The most common adverse events were infections and skin-related adverse events. Lymphopenia was noted in 54.7% of pwMS at month 2 and in 35.0% at month 6. Two pwMS had a newly discovered malignant disease, one breast cancer, and one melanoma, during the first year of treatment. Conclusion: Our real-world data on the effectiveness and safety of cladribine tablets are comparable to the pivotal study and other real-world data with no new safety signals.
Keywords (english)
Languageenglish
Publication typeScientific paper - Original scientific paper
Publication statusPublished
Peer reviewPeer review
Publication versionPublished version
Journal titleJournal of Neuroimmunology
Numberingvol. 382, 578164
p-ISSN0165-5728
DOIhttps://doi.org/10.1016/j.jneuroim.2023.578164
URN:NBNurn:nbn:hr:220:430848
Publication2023-09
Document URLhttps://linkinghub.elsevier.com/retrieve/pii/S0165572823001509
Type of resourceText
Access conditionsInstitutional access
Terms of useLicence In copyright icon
Created on2024-06-24 10:28:31